Abderrahmane Mami Hospital
9
1
1
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
33.3%
3 terminated/withdrawn out of 9 trials
25.0%
-61.5% vs industry average
44%
4 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Epidemiological Features of Emergent Highly Resistant Bacteria in Tunisian Intensive Care Units
Role: lead
The Prevalence of Healthcare-associated Infection in Medical Intensive Care Units in Tunisia
Role: lead
Genotype/Phenotype Correlation With Focus on Lung Function in Primary Ciliary Dyskinesia (PCD)
Role: collaborator
Nasal Nitric Oxide Across Mutations in Primary Ciliary Dyskinesia
Role: collaborator
Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals
Role: lead
Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+)
Role: lead
Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia
Role: lead
Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia
Role: lead
Celiprolol Versus Ditiazem for the Prevention of Postoperative Cardiac Arrythmias in Thoracic Surgery
Role: lead
All 9 trials loaded